Mumbai, July 20
Glenmark Pharmaceuticals Ltd has received the US Food and Drug Administration (USFDA) approval to market Meloxicam oral tablets 7.5 mg and 15 mg.
Meloxicam is the generic version of Boehringer Ingelheim's brand Mobic and is used to treat osteoarthritis.
The drug has clocked annual sales of about $936 million, according to a note from Glenmark. The generic drug will be marketed by Glenmark's US subsidiary, Glenmark Pharmaceutical Inc, which will commence supplying the drug to customers in the US immediately. Glenmark is manufacturing the drug at its solid-oral formulation facility at Goa. This is the third Abbreviated New Drug Application filed by Glenmark from the Goa facility, that has received USFDA approval.